Copenhagen, 2011-02-23 08:31 CET (GLOBE NEWSWIRE) --2010 was a good year for ALK. Revenue increased by 9% (in local currencies) to
DKK 2,140 million with an underlying growth in sales of allergy vaccines of
10%. Reported operating profit (EBITDA) increased by 10% to DKK 287 million.

”We are very pleased with this result, especially when taking into account the
political austerity measures on medicine prices, which we saw last year in the
important German market. In 2010, we also reached an important milestone as,
for the first time in ALK's history, sales reached the DKK 2 billion mark in a
year,” says Jens Bager, President and CEO of ALK.

In 2011, ALK expects a 5% gain in sales of allergy vaccines and an increase in
operating profit (EBITDA) of 25% to DKK 360 million.

Updated strategy and long-term objectives
ALK reviewed its strategy plan in 2010. The strategy plan consists of two focus
areas: I) continued progress in sales and earnings in the base business and II)
global development and further commercialisation of ALK's products through
partnerships.

”With continuous growth in our base business and a clear strategy we have high
expectations to the development of ALK in the years to come,” says Jens Bager.

The new strategy plan also sets ALK's long-term objectives. The aim is to
achieve an annual revenue exceeding DKK 3 billion by 2015 at the latest and an
operating profit (EBITDA) of at least 25% of revenue.

See page 2 in the attached annual report for 2010 for further highlights.

Analyst and investor meeting
The company invites analysts and investors to a meeting with Management today
at 11.00 a.m. at Heerings Gaard, Overgaden neden Vandet 11, 0900 Copenhagen C,
at Nordea. The meeting will be held in English and webcast live on
www.alk-abello.com.

It will be possible to call in with questions. Participants in the conference
call are kindly requested to call in before 10.55 a.m. (CET). Danish
participants should call in on tel +45 7014 0453 and international participants
should call in on tel +44 207 108 63 03.



ALK-Abelló A/S

Jens Bager
President and CEO



For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, mobile +45 2064 1143

FM_03_UK_AR_230211.pdf